JENNA HEFEL: Open Payments
NPI 1770153058 · DUBUQUE, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$280 in 16 payments from 10 companies in 2025. Trend: 2023 $403 · 2024 $523 · 2025 $280
Food & beverage: $280
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $65 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Neurocrine BioSciences, Inc. | 2 | $35 |
| Alkermes, Inc. | 2 | $33 |
| Supernus Pharmaceuticals, Inc. | 1 | $24 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $21 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Axsome Therapeutics, Inc. | 1 | $16 |
| ACADIA Pharmaceuticals Inc | 1 | $15 |
| E.R. Squibb & Sons, L.L.C. | 1 | $14 |
Products named: VRAYLAR, INGREZZA, Qelbree, CAPLYTA, AUSTEDO XR, REXULTI, ARISTADA, UZEDY.
Industry payments across IA — which companies pay providers there.
